Can COVID-19 Antibody Treatment Help In High-Risk Cases? Mayo Clinic, nference Study Shows Potential

Mayo Clinic and nference are jointly conducting artificial intelligence-powered studies evaluating monoclonal antibodies for COVID-19 in patients with an elevated risk of requiring hospitalization.
The first of the two studies focused on Regeneron Pharmaceuticals Inc REGN casirivimab/imdevimab cocktail or REGEN-COV.
Using nference's natural language processing AI software, researchers assessed nearly 1,400 high-risk Mayo Clinic patients with mild to moderate cases of COVID, half of whom were given the antibody treatment.
After two weeks, 1.3% of patients treated with antibodies had been hospitalized, compared to 3.3% of the control group. By the four-week mark, that gap had further widened between the two groups, with 1.6% and 4.8% hospitalization rates, respectively.
The second study used nference's AI to examine the effects of Eli Lilly And Co's LLY bamlanivimab.
The analysis compared the results of bamlanivimab treatment in 2,335 high-risk COVID patients with those of an untreated control group.
Related Content: Distribution Resumes Of Eli Lilly COVID-19 Antibody Therapies
All-cause hospitalization rates were shown to be significantly lower in the antibody-treated group, clocking in between 1.4 and two percentage points lower than those in the control group after two, three, and four weeks.
The researchers also studied ICU admission rates for both groups. The AI analysis found that while the control group's rate hovered around 1% at each interval, the antibody group's average admission rate maxed out at 0.56% after four weeks.
Also Read: Mayo Clinic, nference AI Analysis Find No Real-World Link Between COVID-19 Shots And Clots
Photo by Gerd Altmann from Pixabay

Market News and Data brought to you by Benzinga APIs

Comments

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga